Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00144339
First received: September 2, 2005
Last updated: July 10, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: tiotropium Drug: placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 Mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for:
Tiotropium bromide
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
- Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
Secondary Outcome Measures:
- Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days. ]Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
- Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days ]Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
- Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
- Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
- Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
- Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years [ Time Frame: From day 30 to 4 years ]Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
- Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score [ Time Frame: From month 6 to 4 years ]SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).
- Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days. ]Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
- Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days ]Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
- Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days ]Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
- Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment [ Time Frame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days ]Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
- Time to First Exacerbation [ Time Frame: From Day 1 to 4 years ]Chronic obstructive pulmonary disease (COPD) exacerbation
- Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year [ Time Frame: Day 1 to 4 years ]
- Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation [ Time Frame: Day 1 to 4 years ]
- Number of Exacerbation Days Per Patient Year [ Time Frame: Day 1 to 4 years ]Number of exacerbation days normalized by treatment exposure
- Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization [ Time Frame: Day 1 to 4 years ]
- Number and Percentage of Patients With Time to First Exacerbation Leading to Hospitalization [ Time Frame: From Day 1 to 4 years ]Hazard ratio of time to first exacerbation leading to hospitalization
- Number of Exacerbation Leading to Hospitalization [ Time Frame: From Day 1 to 4 years ]Estimated number of exacerbations leading to hospitalizations per patient year
- Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization [ Time Frame: From Day 1 to 4 years ]Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1 [ Time Frame: Month 1 ]Estimated FEV1 before bronchodilator at Month 1
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1 [ Time Frame: Month 1 ]Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6 [ Time Frame: Month 6 ]Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6 [ Time Frame: Month 6 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12 [ Time Frame: Month 12 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12 [ Time Frame: Month 12 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18 [ Time Frame: Month 18 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18 [ Time Frame: Month 18 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24 [ Time Frame: Month 24 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24 [ Time Frame: Month 24 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30 [ Time Frame: Month 30 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30 [ Time Frame: Month 30 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36 [ Time Frame: Month 36 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36 [ Time Frame: Month 36 ]
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42 [ Time Frame: Month 42 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42 [ Time Frame: Month 42 ]Estimated FEV1 after bronchodilator at Month 42
- Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48 [ Time Frame: Month 48 ]
- Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48 [ Time Frame: Month 48 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1 [ Time Frame: Month 1 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1 [ Time Frame: Month 1 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6 [ Time Frame: Month 6 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6 [ Time Frame: Month 6 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12 [ Time Frame: Month 12 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12 [ Time Frame: Month 12 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18 [ Time Frame: Month 18 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18 [ Time Frame: Month 18 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24 [ Time Frame: Month 24 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24 [ Time Frame: Month 24 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30 [ Time Frame: Month 30 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30 [ Time Frame: Month 30 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36 [ Time Frame: Month 36 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36 [ Time Frame: Month 36 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42 [ Time Frame: Month 42 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42 [ Time Frame: Month 42 ]
- Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48 [ Time Frame: Month 48 ]
- Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48 [ Time Frame: Month 48 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1 [ Time Frame: Month 1 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1 [ Time Frame: Month 1 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6 [ Time Frame: Month 6 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6 [ Time Frame: Month 6 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12 [ Time Frame: Month 12 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12 [ Time Frame: Month 12 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18 [ Time Frame: Month 18 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18 [ Time Frame: Month 18 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24 [ Time Frame: Month 24 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24 [ Time Frame: Month 24 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30 [ Time Frame: Month 30 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30 [ Time Frame: Month 30 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36 [ Time Frame: Month 36 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36 [ Time Frame: Month 36 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42 [ Time Frame: Month 42 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42 [ Time Frame: Month 42 ]
- Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48 [ Time Frame: Month 48 ]
- Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48 [ Time Frame: Month 48 ]
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6 [ Time Frame: Month 6 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12 [ Time Frame: Month 12 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18 [ Time Frame: Month 18 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24 [ Time Frame: Month 24 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30 [ Time Frame: Month 30 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36 [ Time Frame: Month 36 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42 [ Time Frame: Month 42 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48 [ Time Frame: Month 48 ]
- SGRQ total score summarizes the impact of COPD on overall patient's health status.
- Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
- The scale is continuous.
- Rate of decline shows the yearly change of SGRQ total score.
- Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment) [ Time Frame: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days ]On-treatment defined as day 1 to completion of double blinded treatment plus 30 days
- Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days) [ Time Frame: Day 1 to day 1470 ]All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.
- Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause) [ Time Frame: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days ]The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days
- Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days) [ Time Frame: Day 1 to day 1470 ]The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used
| Enrollment: | 5993 |
| Study Start Date: | December 2002 |
| Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent.
- Male or female patients 40 years of age or older.
- Smoking history of at least 10 pack years.
- Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1<70% of FVC and on stable respiratory medication.
Exclusion Criteria:
- Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.
- Myocardial infarction in past 6 months.
- Unstable or life threatening arrhythmia in past year.
- Hospitalization for NYHA heart failure class III or IV in past year.
- Active tuberculosis.
- Asthma.
- Pulmonary resection.
- Malignancy treated with radiation or chemotherapy in past 5 years.
- Respiratory infection in 4 weeks prior to screening.
- Known hypersensitivity to anticholinergic drugs or components.
- Known moderate to severe renal impairment.
- Known narrow angle glaucoma.
- Significant symptomatic BPH or bladder neck obstruction.
- Need for oxygen therapy >12 hr/day.
- Use of oral corticosteroids at unstable doses or >10 mg/day.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00144339
Hide Study Locations
Hide Study LocationsLocations
| United States, Alabama | |
| 205.235.3779 Boehringer Ingelheim Investigational Site | |
| Anniston, Alabama, United States | |
| 205.235.3785 Boehringer Ingelheim Investigational Site | |
| Birmingham, Alabama, United States | |
| 205.235.3804 Boehringer Ingelheim Investigational Site | |
| Jasper, Alabama, United States | |
| 205.235.3795 Boehringer Ingelheim Investigational Site | |
| Mobile, Alabama, United States | |
| United States, Arizona | |
| 205.235.3759 Boehringer Ingelheim Investigational Site | |
| Phoenix, Arizona, United States | |
| United States, California | |
| 205.235.3770 Boehringer Ingelheim Investigational Site | |
| Carmichael, California, United States | |
| 205.235.3778 Boehringer Ingelheim Investigational Site | |
| Escondito, California, United States | |
| 205.235.3810 Boehringer Ingelheim Investigational Site | |
| Lakewood, California, United States | |
| 205.235.3812 Boehringer Ingelheim Investigational Site | |
| Long Beach, California, United States | |
| 205.235.3758 Boehringer Ingelheim Investigational Site | |
| Long Beach, California, United States | |
| 205.235.3800 Boehringer Ingelheim Investigational Site | |
| Los Angeles, California, United States | |
| 205.235.3802 Boehringer Ingelheim Investigational Site | |
| Los Angeles, California, United States | |
| 205.235.3773 Boehringer Ingelheim Investigational Site | |
| Los Angeles, California, United States | |
| 205.235.3786 Pulmonary and Critical Care Medicine | |
| Orange, California, United States | |
| 205.235.3811 Boehringer Ingelheim Investigational Site | |
| Palo Alto, California, United States | |
| 205.235.3741 Boehringer Ingelheim Investigational Site | |
| Rancho Mirage, California, United States | |
| 205.235.3781 Boehringer Ingelheim Investigational Site | |
| San Diego, California, United States | |
| 205.235.3784 Boehringer Ingelheim Investigational Site | |
| San Diego, California, United States | |
| 205.235.3717 Boehringer Ingelheim Investigational Site | |
| San Diego, California, United States | |
| 205.235.3760 Boehringer Ingelheim Investigational Site | |
| Sepulveda, California, United States | |
| 205.235.3711 Boehringer Ingelheim Investigational Site | |
| Stockton, California, United States | |
| United States, Colorado | |
| 205.235.3764 Boehringer Ingelheim Investigational Site | |
| Denver, Colorado, United States | |
| 205.235.3783 Boehringer Ingelheim Investigational Site | |
| Wheat Ridge, Colorado, United States | |
| United States, Connecticut | |
| 205.235.3727 Boehringer Ingelheim Investigational Site | |
| Hartford, Connecticut, United States | |
| 205.235.3808 Boehringer Ingelheim Investigational Site | |
| Hartford, Connecticut, United States | |
| 205.235.3793 Boehringer Ingelheim Investigational Site | |
| Norwalk, Connecticut, United States | |
| 205.235.3815 Boehringer Ingelheim Investigational Site | |
| WEst Haven, Connecticut, United States | |
| United States, Florida | |
| 205.235.3706 Boehringer Ingelheim Investigational Site | |
| Bay Pines, Florida, United States | |
| 205.235.3762 Boehringer Ingelheim Investigational Site | |
| Brandon, Florida, United States | |
| 205.235.3707 Boehringer Ingelheim Investigational Site | |
| Largo, Florida, United States | |
| 205.235.3703 Boehringer Ingelheim Investigational Site | |
| Melbourne, Florida, United States | |
| 205.235.3775 Boehringer Ingelheim Investigational Site | |
| Panama City, Florida, United States | |
| 205.235.3743 Boehringer Ingelheim Investigational Site | |
| Sarasota, Florida, United States | |
| 205.235.3756 Boehringer Ingelheim Investigational Site | |
| Tampa, Florida, United States | |
| 205.235.3739 Boehringer Ingelheim Investigational Site | |
| West Palm Beach, Florida, United States | |
| United States, Georgia | |
| 205.235.3790 Boehringer Ingelheim Investigational Site | |
| Atlanta, Georgia, United States | |
| 205.235.3719 Boehringer Ingelheim Investigational Site | |
| Atlanta, Georgia, United States | |
| 205.235.3716 Boehringer Ingelheim Investigational Site | |
| Augusta, Georgia, United States | |
| 205.235.3794 Boehringer Ingelheim Investigational Site | |
| Stockbridge, Georgia, United States | |
| United States, Idaho | |
| 205.235.3724 Boehringer Ingelheim Investigational Site | |
| Coeur d'Alene, Idaho, United States | |
| United States, Illinois | |
| 205.235.3713 Boehringer Ingelheim Investigational Site | |
| Normal, Illinois, United States | |
| United States, Indiana | |
| 205.235.3768 Boehringer Ingelheim Investigational Site | |
| Indianapolis, Indiana, United States | |
| United States, Iowa | |
| 205.235.3749 Boehringer Ingelheim Investigational Site | |
| Dubuque, Iowa, United States | |
| United States, Kansas | |
| 205.235.3757 Boehringer Ingelheim Investigational Site | |
| Olathe, Kansas, United States | |
| United States, Kentucky | |
| 205.235.3729 Boehringer Ingelheim Investigational Site | |
| Lexington, Kentucky, United States | |
| United States, Louisiana | |
| 205.235.3737 Boehringer Ingelheim Investigational Site | |
| Metairie, Louisiana, United States | |
| 205.235.3788 Boehringer Ingelheim Investigational Site | |
| Shreveport, Louisiana, United States | |
| United States, Maine | |
| 205.235.3750 Boehringer Ingelheim Investigational Site | |
| Bidderford, Maine, United States | |
| United States, Maryland | |
| 205.235.3806 Boehringer Ingelheim Investigational Site | |
| Baltimore, Maryland, United States | |
| United States, Massachusetts | |
| 205.235.3721 Boehringer Ingelheim Investigational Site | |
| Boston, Massachusetts, United States | |
| 205.235.3726 354 Birnie Ave | |
| Springfield, Massachusetts, United States | |
| United States, Michigan | |
| 205.235.3813 Boehringer Ingelheim Investigational Site | |
| Ann Arbor, Michigan, United States | |
| 205.235.3732 Boehringer Ingelheim Investigational Site | |
| Detroit, Michigan, United States | |
| 205.235.3809 Boehringer Ingelheim Investigational Site | |
| Livonia, Michigan, United States | |
| United States, Minnesota | |
| 205.235.3751 Boehringer Ingelheim Investigational Site | |
| Minneapolis, Minnesota, United States | |
| 205.235.3754 Boehringer Ingelheim Investigational Site | |
| Minneapolis, Minnesota, United States | |
| 205.235.3789 Boehringer Ingelheim Investigational Site | |
| Rochester, Minnesota, United States | |
| United States, Missouri | |
| 205.235.3734 Boehringer Ingelheim Investigational Site | |
| Chesterfield, Missouri, United States | |
| 205.235.3814 Boehringer Ingelheim Investigational Site | |
| Kansas City, Missouri, United States | |
| 205.235.3747 Boehringer Ingelheim Investigational Site | |
| St. Louis, Missouri, United States | |
| United States, New Hampshire | |
| 205.235.3763 Boehringer Ingelheim Investigational Site | |
| Lebanon, New Hampshire, United States | |
| United States, New Jersey | |
| 205.235.3797 Boehringer Ingelheim Investigational Site | |
| Cherry Hill, New Jersey, United States | |
| 205.235.3799 Boehringer Ingelheim Investigational Site | |
| Summit, New Jersey, United States | |
| United States, New York | |
| 205.235.3796 Boehringer Ingelheim Investigational Site | |
| Albany, New York, United States | |
| 205.235.3807 Boehringer Ingelheim Investigational Site | |
| Bayshore, New York, United States | |
| 205.235.3816 Boehringer Ingelheim Investigational Site | |
| Bronx, New York, United States | |
| 205.235.3765 Boehringer Ingelheim Investigational Site | |
| Larchmont, New York, United States | |
| 205.235.3748 Boehringer Ingelheim Investigational Site | |
| Mineola, New York, United States | |
| 205.235.3818 Boehringer Ingelheim Investigational Site | |
| New York, New York, United States | |
| 205.235.3722 Boehringer Ingelheim Investigational Site | |
| Rochester, New York, United States | |
| United States, North Carolina | |
| 205.235.3730 Boehringer Ingelheim Investigational Site | |
| Burlington, North Carolina, United States | |
| 205.235.3731 Boehringer Ingelheim Investigational Site | |
| Chapel Hill, North Carolina, United States | |
| 205.235.3736 Boehringer Ingelheim Investigational Site | |
| Durham, North Carolina, United States | |
| 205.235.3745 Boehringer Ingelheim Investigational Site | |
| Elizabath City, North Carolina, United States | |
| 205.235.3712 Boehringer Ingelheim Investigational Site | |
| Winston-Salem, North Carolina, United States | |
| United States, Ohio | |
| 205.235.3723 Boehringer Ingelheim Investigational Site | |
| Cincinnati, Ohio, United States | |
| 205.235.3701 Boehringer Ingelheim Investigational Site | |
| Cleveland, Ohio, United States | |
| United States, Oklahoma | |
| 205.235.3791 Boehringer Ingelheim Investigational Site | |
| Tulsa, Oklahoma, United States | |
| United States, Oregon | |
| 205.235.3820 Boehringer Ingelheim Investigational Site | |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| 205.235.3725 Boehringer Ingelheim Investigational Site | |
| Hershey, Pennsylvania, United States | |
| 205.235.3817 Boehringer Ingelheim Investigational Site | |
| Philadelphia, Pennsylvania, United States | |
| United States, Rhode Island | |
| 205.235.3715 Boehringer Ingelheim Investigational Site | |
| Providence, Rhode Island, United States | |
| United States, Texas | |
| 205.235.3803 Boehringer Ingelheim Investigational Site | |
| El Paso, Texas, United States | |
| 205.235.3787 Boehringer Ingelheim Investigational Site | |
| Houston, Texas, United States | |
| 205.235.3742 Boehringer Ingelheim Investigational Site | |
| Houston, Texas, United States | |
| 205.235.3704 Boehringer Ingelheim Investigational Site | |
| San Antonio, Texas, United States | |
| United States, Utah | |
| 205.235.3752 Boehringer Ingelheim Investigational Site | |
| Salt Lake City, Utah, United States | |
| United States, Virginia | |
| 205.235.3744 Boehringer Ingelheim Investigational Site | |
| Danville, Virginia, United States | |
| 205.235.3782 Boehringer Ingelheim Investigational Site | |
| Fredericksburg, Virginia, United States | |
| 205.235.3771 Boehringer Ingelheim Investigational Site | |
| Lynchburg, Virginia, United States | |
| 205.235.3792 Boehringer Ingelheim Investigational Site | |
| Richmond, Virginia, United States | |
| 205.235.3738 Boehringer Ingelheim Investigational Site | |
| Richmond, Virginia, United States | |
| 205.235.3761 Boehringer Ingelheim Investigational Site | |
| Salem, Virginia, United States | |
| United States, Washington | |
| 205.235.3718 Boehringer Ingelheim Investigational Site | |
| Spokane, Washington, United States | |
| United States, Wisconsin | |
| 205.235.3780 Boehringer Ingelheim Investigational Site | |
| La Crosse, Wisconsin, United States | |
| Argentina | |
| 205.235.101 | |
| Buenos Aires, Argentina | |
| 205.235.104 Hospital de Clinicas José de San Martín | |
| Capital Federal, Argentina | |
| 205.235.107 Policlínica Bancaria | |
| Capital Federal, Argentina | |
| 205.235.103 Hospital Alemán | |
| Capital Federal, Argentina | |
| 205.235.101 Boehringer Ingelheim Investigational Site | |
| Capital Federal, Argentina | |
| 205.235.105 Hospital General de Agudos José María Ramos Mejía | |
| Capital Federal, Argentina | |
| 205.235.108 Hospital General de Agudos Dr. Enrique Tornú | |
| Capital Federal, Argentina | |
| 205.235.109 Hospital Muñiz | |
| Capital Federal, Argentina | |
| 205.235.110 Hospital Privado - Centro Médico de Córdoba S.A. | |
| Parque Velez Sarlfield, Argentina | |
| 205.235.102 Instituto Cardiovascular de Rosario | |
| Rosario, Argentina | |
| 205.235.106 Hospital Cetrángolo | |
| Vicente López, Argentina | |
| Australia, New South Wales | |
| 205.235.0205 Boehringer Ingelheim Investigational Site | |
| Bankstown, New South Wales, Australia | |
| 205.235.0202 Boehringer Ingelheim Investigational Site | |
| Concord, New South Wales, Australia | |
| 205.235.0209 Boehringer Ingelheim Investigational Site | |
| Westmead, New South Wales, Australia | |
| Australia, Queensland | |
| 205.235.0204 Boehringer Ingelheim Investigational Site | |
| Cairns, Queensland, Australia | |
| 205.235.0203 Boehringer Ingelheim Investigational Site | |
| Redcliffe, Queensland, Australia | |
| Australia, South Australia | |
| 205.235.0207 Boehringer Ingelheim Investigational Site | |
| Port Lincoln, South Australia, Australia | |
| Australia, Victoria | |
| 205.235.0206 Boehringer Ingelheim Investigational Site | |
| Box Hill, Victoria, Australia | |
| 205.235.0201 Boehringer Ingelheim Investigational Site | |
| Geelong, Victoria, Australia | |
| Austria | |
| 205.235.0303 Boehringer Ingelheim Investigational Site | |
| Graz, Austria | |
| 205.235.0305 Boehringer Ingelheim Investigational Site | |
| Innsbruck, Austria | |
| 205.235.0304 Boehringer Ingelheim Investigational Site | |
| Leoben, Austria | |
| 205.235.0301 Boehringer Ingelheim Investigational Site | |
| Wien, Austria | |
| 205.235.0302 Boehringer Ingelheim Investigational Site | |
| Wien, Austria | |
| Belgium | |
| 205.235.0439 Boehringer Ingelheim Investigational Site | |
| Anderlecht, Belgium | |
| 205.235.0429 Boehringer Ingelheim Investigational Site | |
| Baudour, Belgium | |
| 205.235.0421 Boehringer Ingelheim Investigational Site | |
| Brugge, Belgium | |
| 205.235.0424 Boehringer Ingelheim Investigational Site | |
| Brussel, Belgium | |
| 205.235.0432 Boehringer Ingelheim Investigational Site | |
| Bruxelles, Belgium | |
| 205.235.0434 Boehringer Ingelheim Investigational Site | |
| Bruxelles, Belgium | |
| 205.235.0422 Boehringer Ingelheim Investigational Site | |
| Dendermonde, Belgium | |
| 205.235.0405 Boehringer Ingelheim Investigational Site | |
| Edegem, Belgium | |
| 205.235.0414 Boehringer Ingelheim Investigational Site | |
| Gent, Belgium | |
| 205.235.0418 U.Z. Gent | |
| Gent, Belgium | |
| 205.235.0417 Boehringer Ingelheim Investigational Site | |
| Herentals, Belgium | |
| 205.235.0402 Boehringer Ingelheim Investigational Site | |
| Ieper, Belgium | |
| 205.235.0409 Boehringer Ingelheim Investigational Site | |
| Kortrijk, Belgium | |
| 205.235.0407 Boehringer Ingelheim Investigational Site | |
| Leuven, Belgium | |
| 205.235.0440 Boehringer Ingelheim Investigational Site | |
| Luxembourg, Belgium | |
| 205.235.0403 Boehringer Ingelheim Investigational Site | |
| Menen, Belgium | |
| 205.235.0406 Boehringer Ingelheim Investigational Site | |
| Merksem, Belgium | |
| 205.235.0404 Boehringer Ingelheim Investigational Site | |
| Middelheim, Belgium | |
| 205.235.0438 Boehringer Ingelheim Investigational Site | |
| Mons, Belgium | |
| 205.235.0437 Boehringer Ingelheim Investigational Site | |
| Namur, Belgium | |
| 205.235.0420 Boehringer Ingelheim Investigational Site | |
| Neerpelt, Belgium | |
| 205.235.0435 Boehringer Ingelheim Investigational Site | |
| Nobressart (ATTERT), Belgium | |
| 205.235.0423 Boehringer Ingelheim Investigational Site | |
| Oostende, Belgium | |
| 205.235.0433 Boehringer Ingelheim Investigational Site | |
| Tournai, Belgium | |
| 205.235.0412 Boehringer Ingelheim Investigational Site | |
| Turnhout, Belgium | |
| 205.235.0413 Boehringer Ingelheim Investigational Site | |
| Turnhout, Belgium | |
| 205.235.0428 Boehringer Ingelheim Investigational Site | |
| Yvoir, Belgium | |
| Brazil | |
| 205.235.510 Servico de Pneumologia | |
| Florianópolis - SC, Brazil | |
| 205.235.508 | |
| Juiz de Fora - MG, Brazil | |
| 205.235.501 | |
| Porto Alegre - RS, Brazil | |
| 205.235.503 | |
| Porto Alegre - RS, Brazil | |
| 205.235.506 | |
| Porto Alegre - RS, Brazil | |
| 205.235.507 Depto.de Medicina Interna-Servico de pneumologia | |
| Porto Alegre - RS, Brazil | |
| 205.235.502 | |
| Rio de Janeiro - RJ, Brazil | |
| 205.235.505 Dep.Medicina Especializada (DEMESP) | |
| Rio de Janeiro - RJ, Brazil | |
| 205.235.511 Departamento de Pneumologia | |
| Salvador - BA, Brazil | |
| 205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar | |
| Santo André - SP, Brazil | |
| 205.235.515 Lar Escola São Francisco / Setor de Pneumologia | |
| São Paulo - SP, Brazil | |
| 205.235.512 | |
| São Paulo - SP, Brazil | |
| 205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina | |
| São Paulo - SP, Brazil | |
| 205.235.513 | |
| São Paulo - SP, Brazil | |
| Czech Republic | |
| 205.235.0712 Boehringer Ingelheim Investigational Site | |
| Benesov, Czech Republic | |
| 205.235.0711 Boehringer Ingelheim Investigational Site | |
| Beroun, Czech Republic | |
| 205.235.0718 Clinic of Functional Diagnostics and Rehabilitation | |
| Brno, Czech Republic | |
| 205.235.0725 University Hospital Brno | |
| Brno, Czech Republic | |
| 205.235.0720 Office of Pulmonology and Respiratory Diseases | |
| Cesky Tesin, Czech Republic | |
| 205.235.0717 Pulmonary Clinic | |
| Hradec Kralove, Czech Republic | |
| 205.235.0705 Boehringer Ingelheim Investigational Site | |
| Jablonec nad Nisou, Czech Republic | |
| 205.235.0726 Private Office of Pulmonary Diseases | |
| Jaromer, Czech Republic | |
| 205.235.0722 Hospital Kromeriz | |
| Kromeriz, Czech Republic | |
| 205.235.0724 District Hospital Kyjov | |
| Kyjov, Czech Republic | |
| 205.235.0704 Boehringer Ingelheim Investigational Site | |
| Lovosice, Czech Republic | |
| 205.235.0702 Boehringer Ingelheim Investigational Site | |
| Marianske Lazne, Czech Republic | |
| 205.235.0703 Boehringer Ingelheim Investigational Site | |
| Plzen, Czech Republic | |
| 205.235.0701 Boehringer Ingelheim Investigational Site | |
| Plzen, Czech Republic | |
| 205.235.0710 Boehringer Ingelheim Investigational Site | |
| Prague 5, Czech Republic | |
| 205.235.0706 Boehringer Ingelheim Investigational Site | |
| Praha 4, Czech Republic | |
| 205.235.0709 Boehringer Ingelheim Investigational Site | |
| Praha 4, Czech Republic | |
| 205.235.0715 Boehringer Ingelheim Investigational Site | |
| Praha 5, Czech Republic | |
| 205.235.0708 Boehringer Ingelheim Investigational Site | |
| Praha 5 - Nove Butovice, Czech Republic | |
| 205.235.0707 Boehringer Ingelheim Investigational Site | |
| Praha 8, Czech Republic | |
| 205.235.0723 Office of Pulmonary and Respiratory Diseases | |
| Prerov, Czech Republic | |
| 205.235.0721 Office of Pulmonary Diseases | |
| Pribor, Czech Republic | |
| 205.235.0713 Boehringer Ingelheim Investigational Site | |
| Strakonice, Czech Republic | |
| 205.235.0714 Boehringer Ingelheim Investigational Site | |
| Tabor, Czech Republic | |
| 205.235.0719 Office of Pulmonology and Respiratory Diseases | |
| Usti nad Orlici, Czech Republic | |
| 205.235.0716 Boehringer Ingelheim Investigational Site | |
| Znojmo, Czech Republic | |
| Denmark | |
| 205.235.0804 Boehringer Ingelheim Investigational Site | |
| Aalborg, Denmark | |
| 205.235.0826 Boehringer Ingelheim Investigational Site | |
| Aalborg SV, Denmark | |
| 205.235.0803 Boehringer Ingelheim Investigational Site | |
| Aarhus, Denmark | |
| 205.235.0831 Boehringer Ingelheim Investigational Site | |
| Copenhagen, Denmark | |
| 205.235.0828 Boehringer Ingelheim Investigational Site | |
| Copenhagen K, Denmark | |
| 205.235.0802 Boehringer Ingelheim Investigational Site | |
| Copenhagen NV, Denmark | |
| 205.235.0821 Boehringer Ingelheim Investigational Site | |
| Frederikshavn, Denmark | |
| 205.235.0832 Boehringer Ingelheim Investigational Site | |
| Frederikssund, Denmark | |
| 205.235.0807 Boehringer Ingelheim Investigational Site | |
| Fåborg, Denmark | |
| 205.235.0805 Boehringer Ingelheim Investigational Site | |
| Hellerup, Denmark | |
| 205.235.0835 Boehringer Ingelheim Investigational Site | |
| Hellerup, Denmark | |
| 205.235.0816 Boehringer Ingelheim Investigational Site | |
| Helsingor, Denmark | |
| 205.235.0811 Boehringer Ingelheim Investigational Site | |
| Hillerød, Denmark | |
| 205.235.0834 Boehringer Ingelheim Investigational Site | |
| Hobro, Denmark | |
| 205.235.0806 Boehringer Ingelheim Investigational Site | |
| Holbæk, Denmark | |
| 205.235.0814 Boehringer Ingelheim Investigational Site | |
| Holstebro, Denmark | |
| 205.235.0801 Boehringer Ingelheim Investigational Site | |
| Hvidovre, Denmark | |
| 205.235.0833 Boehringer Ingelheim Investigational Site | |
| Kalundborg, Denmark | |
| 205.235.0830 Boehringer Ingelheim Investigational Site | |
| Kolding, Denmark | |
| 205.235.0819 Boehringer Ingelheim Investigational Site | |
| Nykobing F., Denmark | |
| 205.235.0810 Boehringer Ingelheim Investigational Site | |
| Næstved, Denmark | |
| 205.235.0809 Boehringer Ingelheim Investigational Site | |
| Odense C, Denmark | |
| 205.235.0815 Boehringer Ingelheim Investigational Site | |
| Randers, Denmark | |
| 205.235.0824 Boehringer Ingelheim Investigational Site | |
| Silkeborg, Denmark | |
| 205.235.0813 Boehringer Ingelheim Investigational Site | |
| Skive, Denmark | |
| 205.235.0822 Boehringer Ingelheim Investigational Site | |
| Skive, Denmark | |
| 205.235.0820 Boehringer Ingelheim Investigational Site | |
| Slagelse, Denmark | |
| 205.235.0808 Boehringer Ingelheim Investigational Site | |
| Svendborg, Denmark | |
| 205.235.0827 Boehringer Ingelheim Investigational Site | |
| Værløse, Denmark | |
| Finland | |
| 205.235.0903 Boehringer Ingelheim Investigational Site | |
| Helsinki, Finland | |
| 205.235.0901 Boehringer Ingelheim Investigational Site | |
| Jyväskylä, Finland | |
| 205.235.0905 Boehringer Ingelheim Investigational Site | |
| Kotka, Finland | |
| 205.235.0904 Boehringer Ingelheim Investigational Site | |
| Lahti, Finland | |
| 205.235.0902 Boehringer Ingelheim Investigational Site | |
| Pori, Finland | |
| France | |
| 205.235.1007 Cabinet Médical | |
| Albi, France | |
| 205.235.1004 Clinique Toulouse Lautrec | |
| Albi cedex 9, France | |
| 205.235.1015 Centre Hospitalier | |
| Barbezieux St Hilaire, France | |
| 205.235.1012 Cabinet Médical | |
| Bourges, France | |
| 205.235.1024 Cabinet Médical | |
| Chamalières, France | |
| 205.235.1006 Centre Hospitalier de Chauny | |
| Chauny cedex, France | |
| 205.235.1005 Polyclinique | |
| Cholet, France | |
| 205.235.1013 Cabinet Médical | |
| La Teste, France | |
| 205.235.1020 Cabinet Médical | |
| Marseille, France | |
| 205.235.1023 Cabinet Médical | |
| Montauban, France | |
| 205.235.1025 Centre Médical Erdre Saint Augustin | |
| Nantes, France | |
| 205.235.1002 Cabinet médical | |
| Nice, France | |
| 205.235.1001 Hôpital Bichat | |
| Paris, France | |
| 205.235.1016 Cabinet Médical | |
| Provins, France | |
| 205.235.1019 Cabinet Médical | |
| Strasbourg, France | |
| 205.235.1009 Centre Hospitalier de Bigorre | |
| Tarbes cedex 9, France | |
| 205.235.1021 Clinique Pasteur | |
| Toulouse, France | |
| Germany | |
| 205.235.1113 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 205.235.1114 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 205.235.1103 Boehringer Ingelheim Investigational Site | |
| Brake, Germany | |
| 205.235.1105 Boehringer Ingelheim Investigational Site | |
| Braunschweig, Germany | |
| 205.235.1104 Boehringer Ingelheim Investigational Site | |
| Bruchsal, Germany | |
| 205.235.1115 Boehringer Ingelheim Investigational Site | |
| Hannover, Germany | |
| 205.235.1109 Boehringer Ingelheim Investigational Site | |
| Kaufbeuren, Germany | |
| 205.235.1108 Boehringer Ingelheim Investigational Site | |
| Lörrach, Germany | |
| 205.235.1102 Boehringer Ingelheim Investigational Site | |
| Lübeck, Germany | |
| 205.235.1110 Boehringer Ingelheim Investigational Site | |
| München, Germany | |
| 205.235.1106 Boehringer Ingelheim Investigational Site | |
| München, Germany | |
| 205.235.1101 Boehringer Ingelheim Investigational Site | |
| Ulm, Germany | |
| 205.235.1107 Boehringer Ingelheim Investigational Site | |
| Weyhe, Germany | |
| 205.235.1112 Boehringer Ingelheim Investigational Site | |
| Wiesloch, Germany | |
| Greece | |
| 205.235.1203 Boehringer Ingelheim Investigational Site | |
| Athens, Greece | |
| 205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital | |
| Athens, Greece | |
| 205.235.1201 Boehringer Ingelheim Investigational Site | |
| Heraklion, Greece | |
| 205.235.1211 Boehringer Ingelheim Investigational Site | |
| Kavala, Greece | |
| 205.235.1204 Boehringer Ingelheim Investigational Site | |
| Larissa, Greece | |
| 205.235.1209 Boehringer Ingelheim Investigational Site | |
| Patra, Greece | |
| 205.235.1210 Boehringer Ingelheim Investigational Site | |
| Patra, Greece | |
| 205.235.1207 Boehringer Ingelheim Investigational Site | |
| Thessaloniki, Greece | |
| 205.235.1206 Boehringer Ingelheim Investigational Site | |
| Thessaloniki, Greece | |
| 205.235.1205 Boehringer Ingelheim Investigational Site | |
| Thessaloniki, Greece | |
| Hong Kong | |
| 205.235.1401 Boehringer Ingelheim Investigational Site | |
| Hong Kong, Hong Kong | |
| 205.235.1403 Boehringer Ingelheim Investigational Site | |
| Hong Kong, Hong Kong | |
| 205.235.1402 Boehringer Ingelheim Investigational Site | |
| Kowloon, Hong Kong | |
| 205.235.1404 Boehringer Ingelheim Investigational Site | |
| Kowloon, Hong Kong | |
| Hungary | |
| 205.235.1310 Boehringer Ingelheim Investigational Site | |
| Budapest, Hungary | |
| 205.235.1309 Boehringer Ingelheim Investigational Site | |
| Budapest, Hungary | |
| 205.235.1308 Boehringer Ingelheim Investigational Site | |
| Budapest, Hungary | |
| 205.235.1303 Boehringer Ingelheim Investigational Site | |
| Budapest, Hungary | |
| 205.235.1311 Boehringer Ingelheim Investigational Site | |
| Budapest, Hungary | |
| 205.235.1318 Boehringer Ingelheim Investigational Site | |
| Debrecen, Hungary | |
| 205.235.1314 Boehringer Ingelheim Investigational Site | |
| Deszk, Hungary | |
| 205.235.1306 Boehringer Ingelheim Investigational Site | |
| Erd, Hungary | |
| 205.235.1315 Boehringer Ingelheim Investigational Site | |
| Farkasgyepü, Hungary | |
| 205.235.1320 Boehringer Ingelheim Investigational Site | |
| Gyula, Hungary | |
| 205.235.1307 Boehringer Ingelheim Investigational Site | |
| Kiskunhalas, Hungary | |
| 205.235.1304 Boehringer Ingelheim Investigational Site | |
| Miskolc, Hungary | |
| 205.235.1317 Boehringer Ingelheim Investigational Site | |
| Mosonmagyarovar, Hungary | |
| 205.235.1301 Boehringer Ingelheim Investigational Site | |
| Pecs, Hungary | |
| 205.235.1313 Boehringer Ingelheim Investigational Site | |
| Solymar, Hungary | |
| 205.235.1305 Boehringer Ingelheim Investigational Site | |
| Sopron, Hungary | |
| 205.235.1319 Boehringer Ingelheim Investigational Site | |
| Szombathely, Hungary | |
| 205.235.1302 Boehringer Ingelheim Investigational Site | |
| Tatabanya, Hungary | |
| 205.235.1316 Boehringer Ingelheim Investigational Site | |
| Törökbalint, Hungary | |
| 205.235.1312 Boehringer Ingelheim Investigational Site | |
| Veszprem, Hungary | |
| Ireland | |
| 205.235.1505 Boehringer Ingelheim Investigational Site | |
| Dublin 15, Ireland | |
| 205.235.1503 Boehringer Ingelheim Investigational Site | |
| Dublin 4, Ireland | |
| 205.235.1501 Boehringer Ingelheim Investigational Site | |
| Dublin 9, Ireland | |
| Italy | |
| 205.235.1631 A. O. SS. Antonio e Biagio e Arrigo | |
| Alessandria, Italy | |
| 205.235.1613 A. O. S. Giuseppe Moscati | |
| Avellino, Italy | |
| 205.235.1618 Ospedale Bellaria | |
| Bologna, Italy | |
| 205.235.1649 Ospedale di Circolo di Busto Arsizio | |
| Busto Arsizio (VA), Italy | |
| 205.235.1635 P. O. Roberto Binaghi | |
| Cagliari, Italy | |
| 205.235.1623 A. O. di Carrara | |
| Carrara (Massa), Italy | |
| 205.235.1645 Ospedale Civile "Zappatoni" | |
| CASSANO D'ADDA (Milano), Italy | |
| 205.235.1617 Ospedale S. Camillo De Lellis | |
| Chieti, Italy | |
| 205.235.1612 A. O. S. Antonio Abate | |
| Erice (Trapani), Italy | |
| 205.235.1622 A. O. S. Anna | |
| Ferrara, Italy | |
| 205.235.1647 A. O. Careggi | |
| Firenze, Italy | |
| 205.235.1646 A. O. di Careggi | |
| Firenze, Italy | |
| 205.235.1615 Ospedale S. Martino | |
| Genova, Italy | |
| 205.235.1603 P. O. di Gubbio | |
| Gubbio (Perugia), Italy | |
| 205.235.1619 A. O. Fratelli Crobu | |
| Iglesias (Cagliari), Italy | |
| 205.235.1648 Ospedale "S. Maria di Collemaggio" | |
| L'Aquila, Italy | |
| 205.235.1624 Ospedale di Macerata | |
| Macerata, Italy | |
| 205.235.1634 P. O. Luigi Sacco | |
| Milano, Italy | |
| 205.235.1639 Ospedale Maggiore | |
| Modica (Ragusa), Italy | |
| 205.235.1629 A. O. S. Luigi Gonzaga | |
| Orbassano (Torino), Italy | |
| 205.235.1604 P. O. R. Silvestrini | |
| Perugia, Italy | |
| 205.235.1601 Presidio Ospedaliero di Cisanello | |
| Pisa, Italy | |
| 205.235.1643 A. O. Santa Maria degli Angeli | |
| Pordenone, Italy | |
| 205.235.1614 Ospedale Misericordia e Dolce | |
| Prato, Italy | |
| 205.235.1607 Università degli Studi di Sassari | |
| Sassari, Italy | |
| 205.235.1608 ASL 1 di Sassari | |
| Sassari, Italy | |
| 205.235.1606 ASL 4 di Terni | |
| Terni, Italy | |
| 205.235.1632 ASL 4 - Distretto 2 | |
| Torino, Italy | |
| 205.235.1633 A. O. Umberto I | |
| Torrette di Ancona (Ancona), Italy | |
| 205.235.1640 P. O. Cà Foncello | |
| Treviso, Italy | |
| 205.235.1602 Ospedale di Voghera | |
| Voghera (Pavia), Italy | |
| Japan | |
| 205.235.1706 Juntendo University Hospital | |
| Bunkyo-ku, Tokyo, Japan | |
| 205.235.1705 Kameda Medical Center | |
| Kamogawa, Chiba, Japan | |
| 205.235.1713 Komaki City Hospital | |
| Komaki, Aichi, Japan | |
| 205.235.1712 Kurume University Hospital | |
| Kurume, Fukuoka, Japan | |
| 205.235.1708 Shinshu University | |
| Matsumoto, Nagano, Japan | |
| 205.235.1702 Iwate Medical University Hospital | |
| Morioka, Iwate, Japan | |
| 205.235.1710 Osaka City University Hospital | |
| Osaka, Osaka, Japan | |
| 205.235.1711 Kinki University Hospital | |
| Osakasayama, Osaka, Japan | |
| 205.235.1701 Hokkaido University | |
| Sapporo, Hokkaido, Japan | |
| 205.235.1703 Tohoku University Hospital | |
| Sendai, Miyagi, Japan | |
| 205.235.1709 Tosei General Hospital | |
| Seto, Aichi, Japan | |
| 205.235.1704 Hiraka General Hospital | |
| Yokote, Akita, Japan | |
| Lithuania | |
| 205.235.1801 Boehringer Ingelheim Investigational Site | |
| Kaunas, Lithuania | |
| 205.235.1802 Boehringer Ingelheim Investigational Site | |
| Kaunas, Lithuania | |
| 205.235.1803 Boehringer Ingelheim Investigational Site | |
| Vilnius, Lithuania | |
| Malaysia | |
| 205.235.1901 Boehringer Ingelheim Investigational Site | |
| Kuala Lumpur, Malaysia | |
| 205.235.1902 Boehringer Ingelheim Investigational Site | |
| Kuala Lumpur, Malaysia | |
| 205.235.1903 Boehringer Ingelheim Investigational Site | |
| Kuala Lumpur, Malaysia | |
| Mexico | |
| 205.235.2005 | |
| Ciudad de Mexico, Mexico | |
| 205.235.2006 Tlalpan 4000, Pabellón 5, EPOC | |
| Ciudad de Mexico, Mexico | |
| 205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B. | |
| Col. Mitras Centro, Monterrey, N.L., Mexico | |
| 205.235.2002 | |
| Guadalajara, Jal., Mexico | |
| 205.235.2009 | |
| Puebla, Mexico | |
| 205.235.2010 Depto. De Ivestigación | |
| Toluca, Mexico | |
| 205.235.2003 | |
| Zapopan, jalisco, Mexico | |
| Netherlands | |
| 205.235.2110 Poli Longziekten | |
| Almelo, Netherlands | |
| 205.235.2105 Lokatie De Lichtenberg | |
| Amersfoort, Netherlands | |
| 205.235.2107 Poli Longziekten | |
| Delft, Netherlands | |
| 205.235.2106 Lokatie Dordwijk | |
| Dordrecht, Netherlands | |
| 205.235.2104 Poli longziekten | |
| Eindhoven, Netherlands | |
| 205.235.2102 Martini Ziekenhuis Groningen | |
| Groningen, Netherlands | |
| 205.235.2112 Poli Longziekten | |
| Harderwijk, Netherlands | |
| 205.235.2115 Poli Longziekten | |
| Heerenveen, Netherlands | |
| 205.235.2101 Atrium medisch centrum | |
| Heerlen, Netherlands | |
| 205.235.2114 Poli Longziekten | |
| Hengelo, Netherlands | |
| 205.235.2108 Poli Longziekten | |
| Leeuwarden, Netherlands | |
| 205.235.2109 Poli Longziekten | |
| Rotterdam, Netherlands | |
| 205.235.2111 Antonius Ziekenhuis | |
| Sneek, Netherlands | |
| New Zealand | |
| 205.235.0211 Boehringer Ingelheim Investigational Site | |
| Auckland, New Zealand | |
| 205.235.0212 Boehringer Ingelheim Investigational Site | |
| Christchurch, New Zealand, New Zealand | |
| Norway | |
| 205.235.2202 Boehringer Ingelheim Investigational Site | |
| Arendal, Norway | |
| 205.235.2201 Boehringer Ingelheim Investigational Site | |
| Fredrikstad, Norway | |
| 205.235.2205 Boehringer Ingelheim Investigational Site | |
| Sandvika, Norway | |
| 205.235.2204 Boehringer Ingelheim Investigational Site | |
| Straume, Norway | |
| Philippines | |
| 205.235.2301 Philippine General Hospital | |
| Manila, Philippines | |
| 205.235.2305 University of Santo Tomas Hospital | |
| Manila, Philippines | |
| 205.235.2302 Philippine Heart Center | |
| Quezon City, Philippines | |
| 205.235.2304 Lung Center of the Philippines | |
| Quezon City, Philippines | |
| 205.235.2303 Veterans Memorial Medical Center | |
| Quezon City, Philippines | |
| Poland | |
| 205.235.2410 Boehringer Ingelheim Investigational Site | |
| Gdansk, Poland | |
| 205.235.2407 Boehringer Ingelheim Investigational Site | |
| Katowice, Poland | |
| 205.235.2408 Boehringer Ingelheim Investigational Site | |
| Krakow, Poland | |
| 205.235.2409 Boehringer Ingelheim Investigational Site | |
| Lodz, Poland | |
| 205.235.2405 Boehringer Ingelheim Investigational Site | |
| Lodz, Poland | |
| 205.235.2403 Boehringer Ingelheim Investigational Site | |
| Warsaw, Poland | |
| 205.235.2402 Boehringer Ingelheim Investigational Site | |
| Warsaw, Poland | |
| 205.235.2401 Boehringer Ingelheim Investigational Site | |
| Warsaw, Poland | |
| 205.235.2404 Boehringer Ingelheim Investigational Site | |
| Wroclaw, Poland | |
| 205.235.2406 Boehringer Ingelheim Investigational Site | |
| Zabrze, Poland | |
| Portugal | |
| 205.235.2504 Centro Hospitalar de Coimbra | |
| Coimbra, Portugal | |
| 205.235.2503 Hospital Pulido Valente | |
| Lisboa, Portugal | |
| 205.235.2505 Hospital de Santa Marta | |
| Lisboa, Portugal | |
| 205.235.2501 Hospital de São João | |
| Porto, Portugal | |
| 205.235.2502 Centro Hospitalar de Vila Nova de Gaia | |
| Vila Nova de Gaia, Portugal | |
| Russian Federation | |
| 205.235.2605 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 205.235.2601 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 205.235.2602 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 205.235.2603 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 205.235.2604 Boehringer Ingelheim Investigational Site | |
| St. Petersburg, Russian Federation | |
| Singapore | |
| 205.235.1904 Boehringer Ingelheim Investigational Site | |
| Singapore, Singapore | |
| 205.235.1905 Boehringer Ingelheim Investigational Site | |
| Singapore, Singapore | |
| 205.235.1906 Boehringer Ingelheim Investigational Site | |
| Singapore, Singapore | |
| Slovakia | |
| 205.235.2701 Boehringer Ingelheim Investigational Site | |
| Bratislava, Slovakia | |
| 205.235.2702 Boehringer Ingelheim Investigational Site | |
| Bratislava, Slovakia | |
| 205.235.2703 Boehringer Ingelheim Investigational Site | |
| Martin, Slovakia | |
| 205.235.2704 Boehringer Ingelheim Investigational Site | |
| Poprad, Slovakia | |
| 205.235.2705 Boehringer Ingelheim Investigational Site | |
| Topolcany, Slovakia | |
| Slovenia | |
| 205.235.2801 Boehringer Ingelheim Investigational Site | |
| Golnik, Slovenia | |
| 205.235.2802 Boehringer Ingelheim Investigational Site | |
| Golnik, Slovenia | |
| 205.235.2805 Boehringer Ingelheim Investigational Site | |
| Kamnik, Slovenia | |
| 205.235.2803 Boehringer Ingelheim Investigational Site | |
| Ljubljana, Slovenia | |
| 205.235.2804 Boehringer Ingelheim Investigational Site | |
| Topolsica, Slovenia | |
| South Africa | |
| 205.235.2908 | |
| Bloemfontein, South Africa | |
| 205.235.2910 | |
| Cape Town, South Africa | |
| 205.235.2912 | |
| Cape Town, South Africa | |
| 205.235.2911 | |
| Durban, South Africa | |
| 205.235.2904 | |
| Durban, South Africa | |
| 205.235.2902 | |
| George, South Africa | |
| 205.235.2905 | |
| Paarl, South Africa | |
| 205.235.2901 Boehringer Ingelheim Investigational Site | |
| Pretoria, South Africa | |
| 205.235.2906 | |
| Somerset West, South Africa | |
| 205.235.2903 | |
| Vanderbijlpark, South Africa | |
| 205.235.2909 | |
| Welkom, South Africa | |
| Spain | |
| 205.235.3014 Complejo Hospitalario Juan Canalejo | |
| A Coruña, Spain | |
| 205.235.3026 Hospital General Universitario de Alicante | |
| Alicante, Spain | |
| 205.235.3011 Complejo Hospitalario Infanta Cristina | |
| Badajoz, Spain | |
| 205.235.3006 Hospital Germans Trias i Pujol | |
| Badalona (Barcelona), Spain | |
| 205.235.3022 Hospital de Cruces | |
| Barakaldo (Bilbao), Spain | |
| 205.235.3003 Hospital Clínic i Provincial de Barcelona | |
| Barcelona, Spain | |
| 205.235.3008 Hospital Vall d'Hebrón | |
| Barcelona, Spain | |
| 205.235.3023 Hospital Dr. Josep Trueta | |
| Girona, Spain | |
| 205.235.3004 Hospital General Universitario de Guadalajara | |
| Guadalajara, Spain | |
| 205.235.3005 Hospital General San Jorge de Huesca | |
| Huesca, Spain | |
| 205.235.3021 Hospital de Jerez de la Frontera | |
| Jerez de la Frontera, Spain | |
| 205.235.3010 Hospital Severo Ochoa | |
| Leganés, Madrid, Spain | |
| 205.235.3013 Clínica Puerta de Hierro | |
| Madrid, Spain | |
| 205.235.3009 Hospital Clínico San Carlos | |
| Madrid, Spain | |
| 205.235.3020 Hospital Universitario La Paz | |
| Madrid, Spain | |
| 205.235.3017 Hospital Ramón y Cajal | |
| Madrid, Spain | |
| 205.235.3036 Hospital 12 de Octubre | |
| Madrid, Spain | |
| 205.235.3031 Hospital Gregorio Marañón | |
| Madrid, Spain | |
| 205.235.3028 Hospital Universitario de la Princesa | |
| Madrid, Spain | |
| 205.235.3033 Hospital General Carlos Haya | |
| Málaga, Spain | |
| 205.235.3027 Complejo Asistencial Son Dureta | |
| Palma de Mallorca, Spain | |
| 205.235.3024 Hospital de Montecelo | |
| Pontevedra, Spain | |
| 205.235.3016 Hospital Universitari de Sant Joan | |
| Reus (Tarragona), Spain | |
| 205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell | |
| Sabadell (Barcelona), Spain | |
| 205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria | |
| Santa Cruz de Tenerife, Spain | |
| 205.235.3039 Hospital Universitario Marqués de Valdecilla | |
| Santander, Spain | |
| 205.235.3035 Hospital Universitario Vírgen del Rocío | |
| Sevilla, Spain | |
| 205.235.3019 Hospital Vírgen de la Macarena | |
| Sevilla, Spain | |
| 205.235.3001 Hospital Mutua Terrassa | |
| Terrassa (Barcelona), Spain | |
| 205.235.3002 Hospital Clínico Universitario de Valencia | |
| Valencia, Spain | |
| 205.235.3034 Hospital La Fe | |
| Valencia, Spain | |
| 205.235.3025 Hospital Universitario Dr. Peset | |
| Valencia, Spain | |
| 205.235.3032 Hospital Arnau de Vilanova | |
| Valencia, Spain | |
| 205.235.3018 Complejo Hospitalario Xeral - Cíes | |
| Vigo, Spain | |
| 205.235.3038 Hospital Clínico Lozano Blesa | |
| Zaragoza, Spain | |
| 205.235.3030 Hospital Miguel Servet | |
| Zaragoza, Spain | |
| Switzerland | |
| 205.235.3203 Universitätsspital Basel | |
| Basel, Switzerland | |
| 205.235.3202 Boehringer Ingelheim Investigational Site | |
| Basel, Switzerland | |
| 205.235.3204 Boehringer Ingelheim Investigational Site | |
| Faltigberg, Switzerland | |
| 205.235.3205 Boehringer Ingelheim Investigational Site | |
| Lugano, Switzerland | |
| 205.235.3206 Boehringer Ingelheim Investigational Site | |
| Montana, Switzerland | |
| 205.235.3208 Boehringer Ingelheim Investigational Site | |
| Winterthur, Switzerland | |
| 205.235.3201 Boehringer Ingelheim Investigational Site | |
| Zürich, Switzerland | |
| Taiwan | |
| 205.235.3301 Boehringer Ingelheim Investigational Site | |
| Taipei, Taiwan | |
| 205.235.3302 Boehringer Ingelheim Investigational Site | |
| Taipei, Taiwan | |
| 205.235.3303 Boehringer Ingelheim Investigational Site | |
| Taipei, Taiwan | |
| Thailand | |
| 205.235.3402 Boehringer Ingelheim Investigational Site | |
| Bangkok, Thailand | |
| 205.235.3403 Boehringer Ingelheim Investigational Site | |
| Bangkok, Thailand | |
| 205.235.3404 Boehringer Ingelheim Investigational Site | |
| Bangkok, Thailand | |
| 205.235.3401 Boehringer Ingelheim Investigational Site | |
| Chiang Mai, Thailand | |
| 205.235.3405 Boehringer Ingelheim Investigational Site | |
| Khon Kaen, Thailand | |
| Turkey | |
| 205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi | |
| Adana, Turkey | |
| 205.235.3506 Hacettepe Tip Fakultesi | |
| Ankara, Turkey | |
| 205.235.3507 Ankara SSK Diskapi Egitim Hastanesi | |
| Ankara, Turkey | |
| 205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi | |
| Ankara, Turkey | |
| 205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye | |
| Erzurum, Turkey | |
| 205.235.3511 Osmangazi Universitesi Tip Fakültesi | |
| Eskisehir, Turkey | |
| 205.235.3503 Tophanelioglu Cad. No: 13/15 | |
| Istanbul, Turkey | |
| 205.235.3505 Istanbul Universitesi Tip Fakültesi | |
| Istanbul, Turkey | |
| 205.235.3504 Cevizli E5 Karayolu | |
| Istanbul, Turkey | |
| 205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi | |
| Istanbul, Turkey | |
| 205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi | |
| Istanbul, Turkey | |
| 205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD | |
| Izmir, Turkey | |
| United Kingdom | |
| 205.235.3615 Boehringer Ingelheim Investigational Site | |
| Aberdeen, United Kingdom | |
| 205.235.3611 Boehringer Ingelheim Investigational Site | |
| Chertsey, United Kingdom | |
| 205.235.3613 Boehringer Ingelheim Investigational Site | |
| Chesterfield, United Kingdom | |
| 205.235.3608 Boehringer Ingelheim Investigational Site | |
| Cottingham, Hull, United Kingdom | |
| 205.235.3605 Boehringer Ingelheim Investigational Site | |
| Exeter, United Kingdom | |
| 205.235.3602 Boehringer Ingelheim Investigational Site | |
| Glasgow, United Kingdom | |
| 205.235.3610 Boehringer Ingelheim Investigational Site | |
| Leeds, United Kingdom | |
| 205.235.3607 Boehringer Ingelheim Investigational Site | |
| Leicester, United Kingdom | |
| 205.235.3604 Boehringer Ingelheim Investigational Site | |
| Middleton, United Kingdom | |
| 205.235.3612 Boehringer Ingelheim Investigational Site | |
| Nottingham, United Kingdom | |
| 205.235.3616 Boehringer Ingelheim Investigational Site | |
| Paisley, United Kingdom | |
| 205.235.3614 Boehringer Ingelheim Investigational Site | |
| Penarth, United Kingdom | |
| 205.235.3603 Boehringer Ingelheim Investigational Site | |
| Plymouth, United Kingdom | |
| 205.235.3609 Boehringer Ingelheim Investigational Site | |
| Sheffield, United Kingdom | |
| 205.235.3601 Boehringer Ingelheim Investigational Site | |
| Solihull, Birmingham, United Kingdom | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
Additional Information:
No publications provided by Boehringer Ingelheim Pharmaceuticals
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT00144339 History of Changes |
| Other Study ID Numbers: | 205.235 |
| Study First Received: | September 2, 2005 |
| Results First Received: | February 21, 2009 |
| Last Updated: | July 10, 2012 |
| Health Authority: | Czech Republic: State Institute for Drug Control (SUKL), CZ-100 41 Prague 10 Hungary: National Institute of Pharmacy, H-1051 Budapest Lithuania: State Medicines Control Agency, LT-01132 Vilnius Poland: Urzad Rejestracji Produktow Leczniczych, Wyrobow, Medycznych i Produktow Biobojczych Russia: Ministry of Healthcare and Social Development of Russian Federation, Moscow Slovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26 Slovenia: Agency for Medicinal Products, SI-1000 Ljubljana Australia: Responsilble Ethics Committee New Zealand: Multicentre Ethics Committee/Medsafe Austria: Bundesamt für Sicherheit im Gesundheitswesen, A-1030 Vienna Belgium: Federal Agency for Medicines and Health Products United States: Food and Drug Administration France: AFFSAPS Hong Kong: Dept. of Health of Hong Kong Italy: Comitato Etico Az. Osp. Univ. Pisana di Pisa Malaysia: Ministry of Health, Malaysia Norway: Norwegian Medicines Agency (Statens Legemiddelverk) Portugal: INFARMED - National Authority of Medicines and Health Products, IP Argentina: A.N.M.A.T. (Administracion Nacional de Medicamentos, Alimentos y Tecnología) Taiwan: Department of Health, Executive Yuan, Taiwan Philippines: Department of Health, Republic of the Philippines Thailand: Ministry of Public Health Finland: Finnish Medicines Agency Singapore: Health Science Authority, Ministry of Health Switzerland: Swissmedic Turkey: Ministry of Health Central Ethics Committee Great Britain: MHRA South Africa: Medicines Control Council |
Additional relevant MeSH terms:
|
Chronic Disease Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Disease Attributes Pathologic Processes Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013